LRMR · Larimar Therapeutics Inc
United States · RS rating 18 · As of 2026-11-03
| Price | 2.54 USD |
|---|---|
| 1-day change | +7.2% |
| RS rating (overall / 1M / 3M / 12M) | 18 / 33 / 15 / 28 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 21 / 5 / 18 |
| Industry group (rank) | Medical-Generic Drugs (136) |
| EPS growth Q/Q | -19.7% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +57.3% |
| Market cap (USD) | $467.5M |